Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York. A portion of the grant will fund The Alliance Fellowship for Myasthenia Gravis Research, at the University of California, Davis, under the direction of Dr. Robert Fairclough, Faculty Researcher/ Principal Investigator. The remainder of the grant will help defer the cost of The Circle News and other operating items.

Myasthenia Gravis is a chronic, sometimes fatal autoimmune neuromuscular disease in which communication between nerve and muscle is impaired, causing muscle fatigue. The disease is highly misdiagnosed. A neurologist is recommended for diagnosis. Global Pharmaceuticals is a leading distributor of pyridostigmine bromide, a key agent used in the treatment of Myasthenia Gravis.

Christopher Mengler, R.Ph., divisional president of Global Pharmaceuticals said: “We are pleased to assist the Myasthenia Gravis Alliance with a grant to further research and awareness of this disease. We recognize the need for research that will hopefully lead to improved quality of life and eventually result in a cure.”

“Our primary goal is to ensure that the proper and appropriate information is forwarded to our myasthenic patients as soon as they are diagnosed,” Executive Director, Debra Santulli-Barone declared, “since the first two years of diagnosis is crucial.”

Ms. Santulli-Barone continued: “I am so grateful to Global Pharmaceuticals for listening to our needs and providing a grant. This will give our members newfound hope. We can now launch a monthly MG Series Support Meeting to address topics such as, 'How to Deal with Your Spouse/Family While Living with MG, Cold Weather Tips, and, Your Options with Medication.'”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine